Gadicke Ansbert's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Nov 4, 2021
- Accession no.
- 0001209191-21-062982
- Filed
- Nov 4, 2021, 5:37 PM ET
- Trade date
- Nov 2, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $2.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| Evnin LukeCIK 0001134657 | 10% Owner |
| MPM BioVentures 2014, L.P.CIK 0001609492 | 10% Owner |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 10% Owner |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 10% Owner |
| MPM Bioventures 2018 (B), L.P.CIK 0001729504 | 10% Owner |
| MPM Asset Management Investors BV2018 LLCCIK 0001734817 | 10% Owner |
| MPM BioVentures 2014 LLCCIK 0001765021 | 10% Owner |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Common Stock | CConversionAcquired | +3,816,760 | –F2 | – | 3,816,760 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | CConversionAcquired | +509,024 | –F2 | – | 4,325,784 | Indirect | Duplicate filing |
| Nov 2, 2021 | Common Stock | PPurchaseAcquired | +100,000 | $20.00 | +$2,000,000 | 4,425,784 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.